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INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal bone marrow failure (BMF) disorders defined by blood cytopenias due to ineffective hematopoiesis, genomic instability, and a predisposition to acute myeloid leukemia (AML). The most commonly recurring genomic alteration in MDS is deletion of chromosome 5q (del(5q)). MDS patients with an isolated del(5q) presenting with anemia, neutropenia, and elevated platelets associated with dysplastic megakaryocytes are considered to have 5q-syndrome. The majority of MDS patients with del(5q) do not exhibit these particular symptoms and, instead, are referred to as "del(5q) MDS". We have recently identified miR-146a, which target the TRAF6 arm of the innate immune pathway, a gene within the deleted region in del(5q) MDS. We posit that multiple genes on chr 5q coordinate TRAF6 activation in del(5q) MDS. A search of annotated genes within or near the CDRs revealed a known inhibitor of TRAF6, TIFAB, on band q31.1. We hypothesize that deletion of TIFAB promotes activation of the TRAF6 complex in human CD34 + cells resulting in hematopoietic defects resembling MDS with del(5q). The overall objectives of this proposal are to (1) determine whether loss of TIFAB in human CD34
+ cells contributes to MDS in mice; (2) to investigate whether deletions of TIFAB activate TRAF6 in MDS; and (3) to determine the consequences of TIFAB deletion on signal transduction in human CD34
+ cells, and whether these could explain features of MDS. In preliminary data from the first 2 year of the proposal, we have evidence that TIFAB is a regulator of human hematopoietic cells. Our key observations show that knockdown of TIFAB in human CD34
+ hematopoietic stem/progenitor cells results in increased survival and proliferation, TIFAB inhibits TRAF6 protein expression and activation, resulting in lower NF-κB activation, and TIFAB expression impacts leukemic cell survival, growth and progenitor function. Given that TIFAB is deleted in many MDS patients, these findings could have major implications in MDS subtypes with deletions of chr 5q. The observation that del(5q) results in inappropriate activation of TRAF6 provides a strong rationale to study the contribution of TIFAB to deregulation of the TRAF6 pathway in MDS.
BODY Task 1. Plasmid constructs and validation (months 1-4): 1a (Complete).
For knockdown of TIFAB in human CD34+ or MDS/AML cell lines, we used RNAi-mediated gene silencing. Lentiviral vectors encoding two independent shRNAs targeting human TIFAB were purchased from OpenBiosystems. The bicistronic lentiviral vector contains a microRNA-adapted shRNA and a CMV-driven turboGFP ( Figure 1A) 1 . 1c (Complete). For qRT-PCR and immunoblot analysis to determine TIFAB knockdown, two independent shRNAs targeting TIFAB (#88 and #89) and a scrambled control vector (shCTL) were transduced into human HL60 and THP1 leukemia cell lines. Two days post transduction, cells were sorted for GFP expression and expanded for an additional 2 days in culture. RNA and protein were collected and examined for TIFAB knockdown by qRT-PCR ( Figure 1B ) and immunoblotting ( Figure 1C ), respectively. In addition, we have also confirmed efficient knockdown in primary human cord blood CD34+ cells ( Figure 2D ). 1d. The original plan involved knocking down both miR-145 and miR-146a in primary hematopoietic cells using a miRNA decoy retroviral vector. Given that more recent findings indicate that miR-146a specifically targets the TRAF6 pathway and its deletion results in many ! 2! MDS-like features in mice 2,3 , we have opted to clone only the miR-146a decoy. We have generated a decoy that knocks down the expression of miR-146a only. To confirm knockdown, we have transduced human CD34+ cells and performed qRT-PCR analysis for miR-146a knockdown. Unfortunately, the miRNA decoy is not efficient at knocking down miR-146a ( Figure 1E ) and does not affect survival ( Figure 1F ) in primary human CD34+ cells (after repeated attempts). Given the technical difficulties of simultaneously knocking down miR-146a and TIFAB, we have focused our attention on the posttranscriptional regulation of TRAF6 (See below).
Task 2. Expression analysis of TIFAB and TIFA in hematopoietic cells (months 1-6): 2a (Complete). Normal expression patterns of TIFA and TIFAB were investigated in human marrow subpopulations. This task is complete.
Task 3. Isolation and infection of CD34+ cells (months 4-18):
3a/b. Human umbilical cord CD34+ cells were obtained and cultured in vitro. CD34+ cells were transduced with shTIFAB-GFP, sorted, and evaluated in vitro. Transduction efficiency was 4% for shTIFAB. As indicated above, knockdown of TIFAB resulted in a reproducible downregulation of TIFAB mRNA by ~50%, which is consistent with the expression in del(5q) MDS patient cells ( Figure 1D ). 3c. As described above, the miR-146a decoy is not efficient at knocking down miR-146a in CD34+ cells despite reasonable transduction efficiency. Given that we are not able to progress with the miR-146a knockdown experiments, we have extended our analysis of TIFAB knockdown to a preleukemic CD34+ cells expressing AML1-ETO fusion (AE) 4 . Since AE CD34+ cells are not fully immortalized, we will determine whether knockdown of TIFAB in AE CD34+ cells will make them malignant. The same assays will be performed as proposed for normal CD34+ experiments (Task 4 and 5). For survival assays, transduced and sorted CD34+ cells were cultured for 4 days and then evaluated for AnnexinV staining. As show in in Figure 2B knockdown of TIFAB resulted in a significant reduction of apoptotic (AnnexinV+) cells ( Figure 2B ).
For clonogenic potential, transduced and sorted CD34+ cells were plated into methylcellulose and then scored for colony formation after 10 days. The number of colonies formed following knockdown of TIFAB was similar as compared to control-transduced cells ( Figure 2C ). When the proportion of colony types was examined, knockdown of TIFAB resulted in slight expansion of CFU-GM colonies at the expense of CFU-G colonies ( Figure 2C) Figure 2D , knockdown of TIFAB did not maintain cells in the immature CD34+ state. Conversely, CD34+ cells with knockdown of TIFAB exhibited an increase of mature CD33+CD34-cells. These observations suggest that lower levels of TIFAB increase survival and proliferation of CD34+ cells but does not promote/maintain immature CD34+ cells.
Task 5. Application of bone marrow transplantation assays and analysis (months 8-36): 5a. We have transduced CD34+ cells with shCTL and shTIFAB and are ready for transplantation into NSGS mice (NOD/SCID mouse with IL2Rγ knockout and transgenic expression of SCF, GM-CSF, and IL-3) 5 . The NSGS colony is maintained by our laboratory and ready for xenotransplantation. For the first experiment, we are prepared to engraft ~10 mice per group (shCTL and shTIFAB). Mice will be analyzed according to our original plan (Task 5b-5d). In addition, we will xenograft AE-CD34+ cells transduced with shCTL or shTIFAB. As for xenotransplantation of normal CD34+ cells, mice receiving AE-CD34+ will be monitored for MDS/AML-like features and hematopoietic defects.
Task 6. Identification of changes in TRAF6 activation and NF-κB signaling by TIFAB (months 10-14):
It was previously reported that TIFAB functions by suppressing TRAF6-mediated NF-κB activation 6, 7 . However, the mechanism by which TIFAB may inhibit TRAF6 and/or NF-κB is not known. Based on our data from Year 1, we find that TIFAB reduces the TRAF6 protein and function. One of the key findings was that TIFAB suppressed LPS-induced NF-kB activation but not TNF-induced NF-kB activation. This observation is consistent with the finding that TIFAB inhibits TRAF6 function and stability. Based on this interesting finding, the experiments in Year 2 were focused on determining the effects of TIFAB on TRAF6-induced NF-kB activation. 6a. We have measured IL-6 and BFL1-A1 (two NF-kB target genes) in CD34+ cells transduced with shTIFAB ( Figure 3A ). We observed an ~1.5 increase in IL6 expression but no significant changes in BFL1A1 in cells with knockdown of TIFAB. This initial observation suggests that TIFAB does not regulate all functions of NF-kB signaling. We are currently evaluating other NF-kB target genes, and determining the activation and expression level of TRAF6 in CD34+ cells with knockdown of TIFAB. 6b. We have devoted a significant effort to dissect the role of TIFAB on NF-kB activation. Our initial efforts have been performed in HEK293 cells using NF-kB luciferase reporter assays:
i.
To investigate the dosage effects of TIFAB on TNF or LPS-induced NF-kB activation, we transfected increasing amounts of pcDNA-TIFAB into HEK293 cells and then stimulated with TNF (1 ng/ml) or LPS (1 ug/ml). As shown in Figure 3C , TIFAB (even at the lowest dose) efficiently inhibited LPS-induced kBsite luciferase activity, but only inhibited TNF-induced kB-luciferase at the highest dose ( Figure 3B ). Conversely, increasing the amount of LPS did not overcome the inhibitory effects of TIFAB on NF-kB activation ( Figure 3D ).
! 4!
ii.
To investigate the dosage effects of TRAF6 on TIFAB repression of NF-kB, we transfected increasing amounts of pcDNA-TRAF6 and pcDNA-TIFAB into HEK293 cells. At all doses examined, TIFAB expression suppressed TRAF6-mediated kB-site activation ( Figure 3E ). iii.
To further understand the specificity of TIFAB-mediated inhibition of NF-kB, we contransfected various NF-kB activators and then assessed the effects of TIFAB ( Figure 4A ). As shown before, TIFAB effectively inhibits TRAF6-mediated activation of kB site-luciferase ( Figure 4B ). Since TRAF6 shares functional and sequence homology with TRAF2, we examined the effects of TIFAB on TRAF2-mediated activation of NF-kB ( Figure 4C ). Interestingly, TIFAB was not able to inhibit TRAF2-mediated kB site-luciferase activity. Since we hypothesize that TIFAB directly inhibits TRAF6, we wanted to determine whether transfecting in IKK (NF-kB kinase) or p65 (NF-kB transcription factor), which are both downstream of TRAF6, could still maintain kB site-luciferase activity in the presence of TIFAB ( Figure 4A ). As expected, IKK or p65 induced kB siteluciferase activity even in the presence of TIFAB ( Figure 4D , 4E). These findings reinforce the hypothesis that TIFAB directly and specifically inhibits TRAF6-mediated NF-kB activation. iv.
To corroborate the NF-kB reporter assays, we investigated the consequences of TIFAB expression on TRAF6 by performing immunoblots ( Figure 4F ). As shown, TIFAB expression results in less TRAF6 protein. v.
TIFAB is 161 amino acids (aa) and contains a fork-head associated domain (FHA) spanning ~ aa 36-91 ( Figure 5A ). To identify the critical region for TIFAB-mediated inhibition of TRAF6, we created TIFAB deletion mutants ( Figure 5A ). Each mutant was fused to the FLAG epitope to conveniently detect expression by immunoblotting. Following transfection into HEK293 cells, the protein expression of the TIFAB deletion mutants was confirmed by FLAG immunoblots ( Figure 5B ). The consequences of TIFAB domain deletions on basal NF-kB activation were first evaluated without TRAF6 expression. As shown in Figure 5C , TIFAB D1-34, D92-161, and D35-161 did not inhibit basal kB-site luciferase activity; in contrast, the level of NF-kB appeared to increase when these mutants were expressed ( Figure 5C ). Mutant D1-91 inhibited basal NF-kB activation ( Figure 5C ). vi.
Next the TIFAB mutants were evaluated for their ability to repress TRAF6-mediated kB site-luciferase activity. As before, full-length TIFAB repressed TRAF6-mediated kB site activity ( Figure 5D ). Similar to the trend observed for basal NF-kB repression, TIFAB D1-34, D92-161, D36-91, and D35-161did not efficiently repress TRAF6-mediated kB site activity ( Figure 5D ). However, D1-91 significantly repressed TRAF6-mediated kB site activity ( Figure 5D ). To extend these observations, we evaluated TRAF6 protein expression following transfection of the TIFAB mutants. Consistent with the kB-luciferase assays, D35-91 and D1-91 reduced endogenous TRAF6 expression ( Figure 5E ). These findings suggest that the inhibitory domain of TIFAB resides within aa 92-161.
To further define the minimal sequence necessary to inhibit TRAF6, we have created additional TIFAB mutants: D1-125, D1-91+D126-161, D126-161, and D91-126 ( Figure 5A ). These mutants are currently being evaluated.
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Task 7. Gene expression analysis (months 16-24).
This task as not been initiated.
Task 8. Validation of targets (months 24-36)
Extra Tasks: Investigating the function of TIFAB by identifying interacting proteins.
The function of TIFAB is not well defined. To further identify the molecular role of TIFAB in MDS/AML cells, we performed a proteomics experiment to identify proteins that bind to TIFAB.
For these experiments, we created a FLAG-tagged TIFAB cDNA in a retroviral vector. HL60 cells were transduced with vector or FLAG-TIFAB. HL60 cells expressing vector or TIFAB were immunoprecipitated with FLAG-containing beads. FLAG-TIFAB complexes were eluted off the beads and run on a polyacrylamide gel for silver stain analysis. Bands that were unique to the lane containing FLAG-TIFAB (and the control bands) were cut from the gel and evaluated by mass spectrometry (box 5 versus 4, and 7 versus 6) ( Figure 6A ). We also cut the band coinciding with the molecular weight of TIFAB (box 8). Based on the mass spectrometry analysis, box 8 contains TIFAB peptides ( Figure 6B ). In addition, we identified unique bands in Box 5 corresponding to Myeloperoxidase (PERM/MPO) ( Figure 6B ). Based on this initial analysis, we have identified at least one unique TIFAB-interacting protein. Future experiments will validate the interaction between TIFAB and MPO and the consequences of this interaction on TRAF6 function. MPO, a lysosomal protein, functions in the host defense system by catalyzing the production of hypohalous acids. Since our recent publication revealed that TRAF6 protein is regulated by lysosomes, we will test the hypothesis that TIFAB-mediated inhibition of TRAF6 occurs through a lysosomal pathway.
KEY RESEARCH ACCOMPLISHMENTS
-Identified an shRNA lentiviral vector containing a GFP reporter that knocks down the expression of human TIFAB by approximately 50% in human CD34+ cells. -Successfully transduced normal CD34+ cells and human leukemic cell lines to evaluate TIFAB knockdown with the shRNA. -Determined that knockdown of TIFAB in human CD34+ cells resulted in increased CD34+ survival and increased proliferation, without affecting differentiation potential. -Discovered that TIFAB suppresses active TRAF6 and reduces TRAF6 protein expression in human cell lines. -Determined that TIFAB suppress NF-κB activation following LPS/TRAF6-mediated stimulation, but not via TRAF2/TNFR. -Narrowed the region of TIFAB that possess the inhibitory function (between aa 91-161).
-Identified a novel TIFAB interacting protein by mass spectrometry. 
CONCLUSIONS
The first year of the project has yielded many interesting results, most of which support our original hypothesis, and allowed us to continue with the majority of goals in the Statement of Work. Overall, the experiments suggest that TIFAB, a novel and uncharacterized protein, exhibits tumor suppressor-like functions in human hematopoietic cells. Our key observations show that (1) TIFAB is primarily expressed in hematopoietic progenitor cells (rather than in primitive hematopoietic stem cells or mature blood cells; (2) knockdown of TIFAB in human CD34+ hematopoietic stem/progenitor cells results in increased survival and altered hematopoietic progenitor function; (3) TIFAB inhibits TRAF6 protein expression and activation, resulting in lower NF-κB activation; and (4) TIFAB expression impacts leukemic cell survival, growth and progenitor function. Given that TIFAB is deleted in many MDS patients, these findings could have major implications in MDS and AML subtypes with deletions of chr 5q.
As indicated above, majority of the goals in the Statement of Work have been accomplished for the first 2 years of the proposal. In addition, our ongoing experiments support our hypothesis, permitting us to continue with our original outline of experiments. However, there have been a few minor alterations to the Statement of Work:
-We have limited our analysis of TIFA as it appears that TIFAB has a major effect on TRAF6 independent of TIFA levels. In addition, TIFA expression did not differ in ! 7! hematopoietic subpopulations. As such, we propose to delay examining TIFA's potential role in linking TIFAB and TRAF6. -Based on our preliminary findings, knockdown of miR-146a does not appear to be feasible in primary human CD34+ cells. As such we have opted to temporarily not focus on miR-146a until we find an alternative strategy. In place of these original experiments, we propose to focus on the direct inhibitory function of TIFAB on TRAF6 by performing detailed structure functional analysis and identification of novel TIFAB interacting proteins. -Since we have optimized consistent knockdown of TIFAB in primary CD34+ cells, we will also investigate the consequences of knocking down TIFAB in preleukemic CD34+ that contain an AML1-ETO fusion gene. As with primary CD34+ cells, we will determine the effects of TIFAB knockdown on proliferation, progenitor function, survival, and xenotransplantation in NSGS mice. 
Personal Statement
Research in my laboratory focuses on the molecular, cellular, and genetic basis of hematologic malignancies, with a specific focus on Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). We have uncovered aberrant activation of the innate immune pathway in MDS, and now find that this activation perturbs normal hematopoietic stem/progenitor (HSPC) function. Therefore, one of the main objectives of my research program is to evaluate the role of the innate immune pathway in normal HSPC and in MDS. Broader initiatives involve characterizing novel candidate genes (including miRNAs) relevant to MDS, dissecting molecular and cellular alterations in MDS (and related hematologic malignancies), and attempting to identify novel therapeutics. In addition, I have extensive experience and ongoing interests in NF-κB signaling and function in immune and stem cells. 
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